Gyre Therapeutics Inc (GYRE)
8.98 -0.11 (-1.21%) 09:36 ET [NASDAQ]
8.94 x 100 9.20 x 100
Realtime by (Cboe BZX)
8.94 x 100 9.20 x 100
Realtime 8.94 -0.15 (-1.65%) 06:48 ET
for Fri, Mar 28th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Assets | |||||
Current Assets | |||||
Cash & Cash Equivalents | 11,813 | 33,509 | 25,175 | 44,347 | 30,360 |
Marketable Securities | 14,858 | N/A | N/A | 2,504 | 48,994 |
Receivables | 24,780 | 16,450 | 17,136 | 1,818 | 3,313 |
Inventories | 6,337 | 4,281 | 6,122 | N/A | N/A |
Other current assets | 5,809 | 1,434 | 843 | 0 | 0 |
TOTAL | $64,786 | $57,221 | $49,653 | $51,476 | $89,510 |
Non-Current Assets | |||||
PPE Net | 23,880 | 23,288 | 17,709 | 970 | 433 |
Investments And Advances | 0 | 0 | 0 | 0 | 2,543 |
Intangibles | 1,705 | 1,698 | 1,856 | 0 | 0 |
Other Non-Current Assets | 35,035 | 34,332 | 15,535 | 3,216 | 2,360 |
TOTAL | $60,620 | $59,318 | $35,100 | $4,186 | $5,336 |
Total Assets | $125,406 | $116,539 | $84,753 | $55,662 | $94,846 |
Liabilities | |||||
Current Liabilities | |||||
Accounts payable and accrued liabilities | 335 | 2,809 | 240 | 6,419 | 5,931 |
Accrued Expenses | 10,615 | 11,935 | 9,264 | 1,467 | 2,476 |
Other current liabilities | 5,022 | 39 | N/A | N/A | N/A |
TOTAL | $19,516 | $20,047 | $12,242 | $14,165 | $17,796 |
Non-Current Liabilities | |||||
Deferred Revenues | N/A | N/A | 145 | 230 | 1,983 |
aiOther Non-Current Liabilities | 1,675 | 10,565 | -1,718 | 408 | 981 |
TOTAL | $7,488 | $18,018 | $294 | $408 | $981 |
Total Liabilities | $27,004 | $38,065 | $12,536 | $14,573 | $18,777 |
Shareholders' Equity | |||||
Shares Outstanding, K | 93,612 | 85,423 | 2,519 | 2,100 | 2,090 |
Common Shares | 86 | 77 | 64 | 31 | 22 |
Retained earnings | -73,453 | -85,538 | 7,395 | -402,694 | -314,761 |
Other shareholders' equity | 35,584 | 95,756 | 31,963 | 0 | 5 |
TOTAL | $98,402 | $78,474 | $72,217 | $41,089 | $76,069 |
Total Liabilities And Equity | $125,406 | $116,539 | $84,753 | $55,662 | $94,846 |